Share Your Expectations for Current and Future Medications to Treat PAH
Clinical importance of component events in Pulmonary Arterial Hypertension clinical trials
Dr. Steeve Provencher invites you to participate in a national survey to improve clinical studies that will evaluate future treatments for PAH. Dr. Provencher is a pulmonologist responsible for the Pulmonary Hypertension (PH) Program at Laval University, University Institute of Cardiology and Pulmonology of Québec, Québec.
If you are a person with PAH or are caring for someone with PAH, your answers are important for this study.